Company news
Artelo Biosciences, Inc. (NASDAQ:ARTL) news
Artelo Biosciences, Inc. news releases on 6ix. Latest, Apr 28, 2025: Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating…
Press releases — page 2
Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12’s Effectiveness in Treating Psoriasis
April 28, 2025
Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025
March 31, 2025
Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results
March 3, 2025
Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex®
February 13, 2025
Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12
January 12, 2025
Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia
December 8, 2024
Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium
November 12, 2024
Artelo Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
November 11, 2024
Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health’s “Preclinical Screening Platform for Pain” Program
November 4, 2024
Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024
Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor
July 14, 2024
Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium
July 2, 2024
Artelo Biosciences Announces Data Supporting Broad Potential Utility of its FABP Inhibitor Platform
July 1, 2024
Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
May 12, 2024
Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy
April 22, 2024
Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update
March 24, 2024
Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12
January 7, 2024
Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
November 12, 2023
Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain Cancers
November 8, 2023
Artelo Biosciences Completes Positive Pre-IND Meeting with FDA for ART26.12
September 6, 2023
Artelo Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
August 9, 2023
Artelo Biosciences Announces Sponsorship of The William A. Devane Early Career Investigator Award at the 33rd Annual International Cannabinoid Research Society Symposium
June 27, 2023
Artelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society Symposium
June 26, 2023
Artelo Biosciences Selected for Oral Presentation to Report Positive Research Findings on ART12.11 at the 33rd Annual International Cannabinoid Research Society Symposium
June 6, 2023
Artelo Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
May 10, 2023
Artelo Biosciences Initiates the Phase 2a Portion of its CAReS Trial EvaluatingART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
April 24, 2023
Artelo Biosciences Reports Fiscal 2022 Year-End Financial Results and Provides Business Update
March 30, 2023
Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
February 1, 2023
Artelo Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
November 7, 2022
Artelo Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
August 8, 2022
Artelo Biosciences Completes Enrollment of the First Three Cohorts in its CAReS Study Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
July 18, 2022
Artelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5 Inhibitor, in Alleviating Chemotherapy-Induced Pain
June 26, 2022
Artelo Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update
May 11, 2022
Artelo Biosciences Reports Positive Pre-clinical Results for Lead Program in Cancer-Related Cachexia
April 12, 2022
Artelo Biosciences Reports Four-Month 2021 Financial Results in Connection with its Amended Fiscal Year End and Provides Business Update
March 20, 2022
Artelo Biosciences Reports Fiscal 2021 Year-End Financial Results and Provides Business Update
November 28, 2021
Artelo Biosciences Reports Third Quarter Fiscal 2021 Financial Results and Provides Business Update
July 11, 2021
Artelo Biosciences Announces Two Poster Presentations Featured at the 31st Annual ICRS Symposium
June 21, 2021
Artelo Biosciences Reports Second Quarter Fiscal 2021 Financial Results and Provides Business Update
April 12, 2021
Artelo Biosciences Doses First Patient in CAReS Study with ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
April 11, 2021
Artelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to Board of Directors
March 8, 2021
Artelo Biosciences Announces Positive Pre-Clinical Data Associated with Proprietary CBD Cocrystal
February 16, 2021
Artelo Biosciences Announces Appointment of Andrew Yates, Ph.D. as Senior Vice President and Chief Scientific Officer
February 15, 2021
Artelo Biosciences Receives $3.0 Million in Net Proceeds from Exercise of Warrants
February 7, 2021
Artelo Biosciences Announces Research Collaboration with Trinity College Dublin to Investigate ART27.13 for the Treatment of Cancer Cachexia
February 1, 2021
Artelo Biosciences Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Update
January 13, 2021
Artelo Biosciences Files Patent Application for New Formulation of ART27.13
December 8, 2020
Artelo Biosciences Announces Appointment of Senior Pharmaceutical Executive Gregory R. Reyes, M.D., Ph.D., to Board of Directors
December 1, 2020
Artelo Biosciences Announces Clinical Trial Authorization to Commence Cancer Appetite Recovery Study for the Treatment of Cancer-Related Anorexia and Weight Loss
November 15, 2020
Artelo Biosciences Reports Fourth Quarter and Fiscal 2020 Year-End Financial Results and Provides Business Update
November 3, 2020